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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is 17alpha hydroxyprogesterone effective for preventing preterm labor in high risk women?”.
STUDY DESIGN: Review of one randomized, double blind, controlled trial, one randomized,
double blind, placebo controlled trial and one randomized controlled trial published in English
between 2015 and 2018.
DATA SOURCES: All three studies were gathered from peer- reviewed journals and found
using PubMed.
OUTCOMES MEASURED: Preterm delivery defined as birth less than 37 weeks gestation for
Facchinetti et al., Shadab et al. and Winer et al.6,7,8
RESULTS: The RCT performed by Facchinetti et al. showed no statistically significant
reduction in rates of preterm labor in the patients treated with 17 alpha-hydroxyprogesterone in
comparison with the control group (p = 0.949). The preterm birth rate in the progesterone group
was 23% vs. 22% in the control group.6 Similarly, Winer et al. found that progesterone
supplementation was not effective in reducing rates of preterm labor with p>0.99. The preterm
birth rate in the progesterone group was 45% vs 44% in the control group.8 Conversely, Shadab
et al. found significant reduction of preterm birth rates treating with 17-alpha
hydroxyprogesterone compared to a control group (p<0.05). The preterm birth rate in the
progesterone group was 28.79% vs 59.09% in the control group.7
CONCLUSIONS: The three RCTs utilized for this review did not hold consistent data in
determining whether 17 alpha-hydroxyprogesterone supplementation is effective in reducing
rates of preterm birth. Facchinetti et al. and Winer et al. demonstrated no statistically significant
reduction in preterm birth rates whereas Shadab et al. found a statistically significant reduction in
rates.6,7,8 The research utilized for this review held inconclusive results and revealed limitations
within each study. Further research is needed to better evaluate the effects of 17 alpha
hydroxyprogesterone supplementation in reducing preterm birth rates.
KEYWORDS: 17 alpha-hydroxyprogesterone, premature birth
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INTRODUCTION
Premature labor is defined as birth before 37 weeks gestation. It is the number one cause
of infant death, and despite major medical advancements, the rates are continuing to rise.1
Prematurity is attributed as a cause in more than 75% of deaths during the neonatal period.2 It is
closely linked to various developmental disabilities as well as major health conditions and
chronic defects.2
Preterm labor occurs in up to 10% of labors in the US and up to 25% of labors in
developing countries.3 About 6% of premature infants die due to secondary complications
associated with being premature.2 Premature labor accounts for healthcare costs up to $26.2
billion annually.1 Although the exact number is not estimated, it is known that preterm labor is
strongly linked to many long term disabilities, resulting in an unreportable number of health care
visits through the rest of the baby’s life.1
There are many iatrogenic conditions known to contribute to rates of preterm labor
including kidney disease, preeclampsia, and gestational diabetes.3 There are also many
spontaneous and infectious etiologies including preterm premature rupture of membranes
(PPROM), multiple pregnancy, and cervical dysfunction.3 Prematurity rates rise in underweight
mothers, with BMIs below 18 kg/m2.3 It is thought that these women are too malnourished to
support the fetus long term. Globally, major risk factors include infectious diseases like malaria,
HIV, and tuberculosis.3
Conventional therapies to prevent preterm labor are limited and lack efficacy in long term
prevention. A common therapy utilized is cervical cerclage, a procedure that surgically sutures a
women’s cervix closed to prevent preterm dilation and to prolong the time until labor.4 Studies
have been shown that cervical cerclage greatly lacked efficacy in women with a shortened cervix
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of less than 25mm. Short term therapy includes administering magnesium sulfate to laboring
mothers to delay contractions.4 This therapy is completely ineffective at delaying labor longterm. Lifestyle modifications have been shown to drastically improve rates of preterm labor.
These modifications include cigarette smoking cessation, decreased alcohol consumption, and
bedrest.4
Although there are major medical initiatives to treat and prevent the complications arising
from preterm labor, it still affects 1 in 10 US babies.3 Advanced mid-level providers, including
physician assistants, who specialize in areas such as OB/GYN and neonatology commonly
encounter preterm labor and it’s subsequent consequences regularly. With more efficient
prevention therapies, providers will be better able to treat preterm labor and prevent infant
mortality and morbidity.
Progesterone is a hormone that is imperative in a women’s ability to become pregnant
and maintain a pregnancy. Research evidence has suggested that labor is associated with a
preceding withdrawal of progesterone action at the site of the uterus.5 There are many
mechanisms proposed to explain the direct physiology in how progesterone affects labor. It has
been shown that progesterone levels directly coincide with myometrial contractility, cervical
effacement, placental corticotropin releasing hormone, and amniotic fluid production. It has also
been shown that progesterone can directly prevent apoptosis of term fetal membranes, preventing
PPROM and subsequent preterm birth.5 Many studies have shown that progesterone may block
unwanted contractions before reaching term and subsequently can help retain a pregnancy.7
Progesterone therapies including suppositories and injections, have been shown to greatly
reduce rates of preterm birth and neonatal death. There is a vast amount of research on the effects
progesterone has on preventing preterm labor. Particularly, progesterone therapy is especially
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useful for patients in which cervical cerclage is not indicated or is ineffective.4 It is known that
preventing preterm birth is favorable over trying to treat the adverse outcomes that arise from
prematurity.4 This paper evaluates three randomized controlled trials (RCTs) evaluating efficacy
of 17-alpha hydroxyprogesterone to prevent preterm labor in women considered to be high risk.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is 17-alpha
hydroxyprogesterone effective for preventing preterm labor in high risk women?”.
METHODS
Three randomized controlled trials (RCTs) were selected for this review. The key words
utilized to search for these studies included 17 alpha-hydroxyprogesterone and premature births.
All three articles were published in peer-reviewed journals, in English, between 2015-2018. The
RCTs were found utilizing PubMed search engine, and articles were selected based on their
ability to answer my clinical question with my patient-oriented outcome of rates of preterm birth.
Inclusion criteria consisted of studies that were RCTs published before 2014 and utilized human
subjects. Exclusion criteria consisted of studies published before 2014 that were not RCTs. The
statistics utilized to analyze these outcomes included p-value, relative risk ratio (RRR), absolute
risk ratio (ARR), and numbers needed to treat (NNT).
The population of interest included women with high risk for preterm labor. Although
“high risk” was defined differently by each study, generally it included women with singleton
pregnancies with cervical length of 25mm or less, who have had an arrested preterm labor, who
have a previous history of preterm birth, who have a history of cervical surgery or uterine
malformation or have had prenatal exposure to DES6,7,8. All three randomized controlled trials
utilized a 17-alpha hydroxyprogesterone intra-muscular injection as the intervention of study. In
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the study conducted by Facchinetti et al, the intervention utilized was a 341mg intramuscular
injection of 17 alpha-hydroxyprogesterone caproate given weekly until 36 weeks gestation. This
group was compared to a control group.6 In the study conducted by Shadab et al, the intervention
utilized was a 250mg intramuscular injection of 17 alpha-hydroxyprogesterone caproate given
weekly until 37 weeks gestation. This was compared to a group given a placebo of Neurobion, a
combination B vitamin.7 The study conducted by Winer et al, utilized an intervention of 500mg
intramuscular injection of 17 alpha-hydroxyprogesterone caproate given weekly until 36 weeks
gestation or until preterm birth. This was compared to a control group.8 The outcome measured
in all three RCTs was rates of preterm labor defined as less than 37 weeks gestation.
OUTCOMES MEASURED
This EBM review utilized the outcome of rates of preterm labor. All three RCTs utilized
had identical definitions of preterm labor, birth before 37 weeks gestation.
RESULTS
Facchinetti et al. conducted a double blind, RCT utilizing obstetric units from five
tertiary care-level university hospitals in Northern Italy. 6 Women were eligible who had
singleton pregnancies between 22 and 31 6/7 weeks gestation who had been admitted to the
hospital because of a first threatened preterm labor episode. That was defined as the
simultaneous presence of contraction at greater than six in 30 minutes and had cervical changes
consistent with shorting, softening or dilating on manual exam. 6 Of these women, those who
were given tocolysis and corticosteroids for fetal lung maturation and remained at risk for
preterm birth due to shortened cervical length (<25mm) were eligible to participate in the study.
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Table 1. Demographics & Characteristics of Included Studies
Study
Type #
Age
Inclusion
Exclusion
W/D Interventions
Pts (yrs) Criteria
Criteria
RCT 254 31.8 Singleton
Hx PTB,
19
341mg IM 17 alphaFacchinetti6
± 5.4 pregnancies
multiparity,
hydroxyprogesterone
(2017)
with cervical PROM, fetal and
caproate weekly
length of
maternal
until 36 weeks
25mm or
conditions
gestation
less, who
indicating
have had an
delivery,
arrested
Mullerian
preterm
malformations,
labor, and no prior cervical
past history
surgery, presence
of preterm
of regular uterine
births
contractions at
discharge
Shadab7
RCT 132 >20
Singleton
Correctable
13
250mg IM 17 alpha(2018)
years pregnancies
causes including
hydroxyprogesterone
who have a
patients with a
caproate weekly
previous
history of
until 37 weeks
history of
delivery
gestation
preterm birth somewhere else,
first trimester
8
Winer
RCT 105 >18
Women with Cervical dilation 2
500mg IM 17OHP(2015)
years a history of
greater than 3
C weekly until 36
spontaneous
cm,
weeks gestation or
preterm birth chorioamnionitis,
PTB
or of cervical PROM, placenta
surgery, a
previa,
uterine
multiparity,
malformation severe IGR,
or prenatal
major structural
exposure to
or chromosomal
DES
fetal
abnormality,
maternal or fetal
disease requiring
induced PTB,
progestogen
therapy before
inclusion,
ongoing
anticonvulsant
treatment or
participation in
other treatment
trial
Table Note: PTB = Preterm birth, PROM = Premature Rupture of Membranes, IGR = Intrauterine
Growth Restriction
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The women in this study could not have a history of previous preterm birth. Refer to Table 1 for
exclusion criteria.6 There were 257 eligible women, 254 opted to participate. Subjects were
randomized and 87 women were allocated to the 17 alpha-hydroxyprogesterone caproate group
and 81 were allocated to the control group. Of the 168 women who participated in either the IM
progesterone or control groups, 8 dropped out and 3 more were excluded from the data analysis
due to incomplete data collection. In total, 80 women in the IM progesterone group and 77
women in the control group were analyzed.6 In the IM progesterone group, 23% (18/80) of
mothers had preterm deliveries and in the control group 22% (17/77) of mothers had preterm
deliveries. There was no statistically significant difference between groups with p=0.949.
Statistical significance is noted as p<0.05 (Table 2). The relative risk reduction (RRR) was 0.013, the absolute risk reduction (ARR) was 0.01 and the numbers needed to treat (NNT) was 100 (Table 3).6 An independent data monitoring committee reviewed the data for patient safety.
This study was prematurely discontinued due to interim analysis revealing unexpected lack of
efficacy associated with a safety concern regarding another treatment group utilized within the
study. No safety concerns were noted within the study regarding the IM 17 alphahydroxyprogesterone caproate treatment group.6
A study conducted by Shadab et al. in an obstetrics outpatient department included
women with singleton pregnancy at less than 20 weeks gestational age with a previous preterm
birth.7 Refer to Table 1 for exclusion criteria. Of the 145 patients who opted to participate in the
study, 13 were excluded from data analysis due to incomplete records or lost to follow-up. A
total of 132 patients were included. Patients were randomized to group A or group B. Group A
subjects received IM progesterone weekly while group B received a placebo of Neurobion.7 The
progesterone group had a preterm delivery rate of 28.79% (19/66) and the placebo group had a
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rate of 59.09% (39/66). There was a statistically significant difference between groups with a
p<0.05 (Table 2). The RRR was 0.741, the ARR was 0.303, and the NNT was 4 (Table 3).7 The
study did not address any specific safety concerns but does note that they did not compare any
side effects of the drug. The researchers do report that there was no complaint regarding adverse
effects or complications secondary to the progesterone injections.7
A study conducted by Winer et al. assessed patients from 11 university hospitals in
France who were between 20 and 31 weeks of gestation and were considered to be high risk for
preterm birth.8 Inclusion criteria included women with an asymptomatic singleton pregnancy
with a history of either preterm birth or cervical surgery, uterine malformation or prenatal DES
exposure. Women had to be at least 18 years old, agree to regular follow-up and provide written
informed consent. Refer to Table 1 for exclusion criteria.8 A total of 105 women who met
inclusion criteria were randomized into 2 groups. Fifty-one women were allocated to the IM
progesterone group while 54 women were allocated to the control group. A total of 2 subjects
were lost to follow up. In this study, if a women was admitted before 34 weeks gestation with
preterm labor, they were given tocolysis and a course of 12mg betamethasone IM.8 Women were
allowed to remain in the study if labor did not occur. The progesterone group had a preterm
delivery rate of 45% (23/50) and the control group had a rate of 44% (24/53). There was no
statistically significant difference between groups with a p>0.99 (Table 2).8 The RRR was 0.018, the ARR was -0.01, and the NNT was -100 (Table 3). The study did not discuss any
adverse effects of the treatment utilized or safety concerns.8
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Table 2. Premature Birth Rate and p-value by Study
Study

Progesterone Group

Control Group

P-value

Facchinetti et al.6

18 (23%)

17 (22%)

0.949

Shadab et al.7

19 (28.79%)

39 (59.09%)

p<0.05

Winer et al.8

23 (45%)

24 (44%)

p>0.99

Statistical significance as p<0.05
Table 3. Calculations for Treatment from Facchinetti et al, Shadab et al., Winer et al.
Study

EER

CER

RRR

ARR

NNT

Facchinetti et al.6

0.77

0.78

-0.013

-0.01

-100

Shadab et al.7

0.7121

0.4091

0.741

0.303

4

Winer et al.8

0.55

0.56

-0.018

-0.01

-100

DISCUSSION
Globally, prematurity is the leading cause of death in babies less than 1 month old and
the second leading cause of death in children less than 5 years old.8 It is evident that preventing
premature births will prevent millions of deaths and many major neonatal complications. This
systemic EBM review was created to better understand the effects of 17 alphahydroxyprogesterone caproate in preventing preterm labor in high risk women. Due to the
conflicting evidence of the three randomized, controlled trials utilized, there is still not a clear
stance on this topic.
The numbers needed to treat (NNT) values calculated for each of these studies varied
from -100 to 4.6,7,8 Facchinetti et al. and Winer et al. surprisingly had the exact same value for
NTT of -100. This value indicates a very insignificant effect of progesterone supplementation at

8
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preventing preterm birth.6,8 However, Shadab et al. had a NNT of 4, indicated a very strong and
large treatment effect and clinical significance.7
Facchinetti et al. addressed limitations of their study including it’s premature
discontinuation due to lack of efficacy and some safety concerns regarding another treatment
group they utilized.6 They report that the likelihood of the study supporting evidence that the
progesterone treatment group decreased rates of preterm birth was extremely unlikely after the
interim data analysis. The study reports that utilizing women with a previous preterm birth would
have overestimated the efficacy of progesterone because they acknowledge the many established
studies supporting the efficacy of progesterone for women with that significant history.6 Shadab
et al. notes their limitations include their lack of comparing side effects of the drugs. They
recommend further studies to evaluate possible adverse effects or complications that may arise
from utilizing 17 alpha-hydroxyprogesterone.7 Lastly, Winer et al. recognizes multiple
limitations of their study. The first is the high rate of cerclage placement among their subjects.
They report that 38% of their control group and 45% of their treatment group had a cerclage
placed prior to their enrollment in the study.8 Another limitation discussed is their early
discontinuing of the study due to futility noted at interim analysis.8 They also note that the
progesterone injections were initiated around 24 weeks gestation in their subjects, potentially too
late in pregnancy to have observed the full treatment effect progesterone injections had the
potential to achieve. Finally, Winer et al. notes that neither the investigators of the study nor the
participants were blinded to the allocation. The researchers remark that they believe the data
analysis revealed no bias associated with their lack of blinding due to their insignificant
difference in data.8 Limitations within this literature review include selection of articles with
varying inclusion criteria. Two studies, Shadab et al. and Winer et al. utilized women with a
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history of preterm birth as inclusion criteria into their studies, however Facchinetti et al. used it
as exclusion criteria. Reviewing literature with more cohesive inclusion and exclusion criteria
may be a future consideration to enhance the validity of the data. Overall, these studies all
exhibited various limitations that may have contributed to their outcomes.
Although the use of progesterone in preventing preterm labor is not considered to be a
new therapy, there is still a great amount of conflicting thought on its use. The US Food and
Drug Administration (FDA) approved progesterone supplementation for reducing the risk of
recurrent preterm birth in women with a history of at least one prior spontaneous preterm
delivery in 2011.5 Although it is approved, there is still major controversy over the optimal
formulation, dosing, and route of administration.5
CONCLUSION
This EBM review of three RCTs has provided conflicting evidence as to whether 17
alpha-hydroxyprogesterone is effective in preventing preterm labor in high risk women.
Facchinetti et al. and Winer et al. failed to provide sufficient evidence that there is a statistically
significant effect of progesterone injections.6,8 Conversely, Shadab et al. did provide evidence
that progesterone injections have a large treatment effect in preventing preterm labor.7
Future study is warranted to evaluate the generalizability of IM progesterone
supplementation in preventing preterm labor among women. The RCT that revealed strong
clinical significance of progesterone injections to prevent preterm labor was the study with the
lowest dose of progesterone administered and the most generalized patient population. To better
evaluate the effect of this treatment, more studies should be conducted utilizing a more general
population such as any women who have previously had a preterm birth.
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The inconsistency of these study results indicates that more research should be done to
better understand the true effects of progesterone supplementation. Because preterm labor is so
prevalent and rates continue to rise despite major medical advancement, it is imperative that
more therapies are explored to better prevent preterm labor and/or treat its subsequent
consequences.
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